
News|Articles|October 1, 2002
Xendos study: Orlistat plus diet prevents, delays diabetes onset in obese patients
Orlistat (Xenical) in combination with diet and lifestyle changes significantly prevents obese patients from developing type 2 diabetes, say researchers involved in this 4-year study presented at the 9th International Congress on Obesity, Sao Paulo, Brazil. They add that this is the first time a weight loss drug has been shown to prevent or delay the onset of type 2 diabetes in an at-risk population.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Researchers discover new pathway to fight liver inflammation
2
Weekly autoinjector Leqembi is available for treatment initiation in Alzheimer’s
3
Employer health care costs projected to rise 9.5% in 2027, report finds
4
Anti-inflammatories instead of antifungals for seborrheic dermatitis
5
























